npj Precision Oncology (Feb 2024)

NF1 mutations as biomarker of response to immune checkpoint blockades for lung adenocarcinoma patients

  • Jean-Stéphane Giraud,
  • Anne Jouinot,
  • Eric Pasmant,
  • Camille Tlemsani

DOI
https://doi.org/10.1038/s41698-024-00524-x
Journal volume & issue
Vol. 8, no. 1
pp. 1 – 6

Abstract

Read online

Abstract Little is known about immune checkpoint inhibitors (ICI) response of NF1-mutated lung adenocarcinomas. 341/4,181 (8.2%) TCGA lung adenocarcinomas samples have a somatic NF1 mutation. NF1-mutated tumors have higher TMB (p < 0.0001), higher expression of immune genes (“hot phenotype”) and higher CD8 + T cell (p = 0.03) and macrophage (p = 0.02) infiltrations compared to NF1 wild-type tumors. NF1 mutation status appears as a candidate predictive biomarker for ICI response in lung adenocarcinoma patients.